Literature DB >> 8437024

Presence of T-cell subset abnormalities in newly diagnosed cases of multiple sclerosis and relationship with short-term clinical activity.

M Eoli1, M Ferrarini, A Dufour, S Heltaj, L Bevilacqua, G Comi, V Cosi, G Filippini, V Martinelli, C Milanese.   

Abstract

Abnormalities of T-cell subsets in patients with multiple sclerosis are well known; in order to assess whether immunological abnormalities are relevant in the pathogenesis of the disease after its clinical onset, peripheral blood lymphocyte subsets (CD3+, CD4+, CD4(+)-CD45RA+, CD4+CD45RA-, CD8+, CD8+CD57+, CD57+, CD25+) were analysed serially in 25 patients at the first clinical episode suggestive of inflammatory demyelinating disease and in an equal number of age- and sex-matched controls. During the follow-up period (12-18 months, mean 14) 6 of 25 patients presented new relapses: in this subgroup of patients, significant changes in CD4+ ratio (% CD4+CD45RA-/%CD4+CD45RA+) were detected in comparison both with healthy controls and with clinically stable patients. Patients clinically stable at follow-up did not display immunological abnormalities, regardless of the presence or absence of cerebrospinal fluid and/or magnetic resonance imaging alterations consistent with multiple sclerosis. These findings suggest a possible prognostic role of early T-cell subset imbalance in multiple sclerosis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8437024     DOI: 10.1007/bf00858721

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  26 in total

1.  Decrease of suppressor inducer (CD4+2H4+) T cells in multiple sclerosis cerebrospinal fluid.

Authors:  M Chofflon; H L Weiner; C Morimoto; D A Hafler
Journal:  Ann Neurol       Date:  1989-05       Impact factor: 10.422

2.  Antibodies to common leukocyte antigen p220 influence human T cell proliferation by modifying IL 2 receptor expression.

Authors:  J A Ledbetter; L M Rose; C E Spooner; P G Beatty; P J Martin; E A Clark
Journal:  J Immunol       Date:  1985-09       Impact factor: 5.422

3.  Loss of functional suppression is linked to decreases in circulating suppressor inducer (CD4+ 2H4+) T cells in multiple sclerosis.

Authors:  M Chofflon; H L Weiner; C Morimoto; D A Hafler
Journal:  Ann Neurol       Date:  1988-08       Impact factor: 10.422

Review 4.  Diagnosis and classification of multiple sclerosis.

Authors:  W I McDonald; A M Halliday
Journal:  Br Med Bull       Date:  1977-01       Impact factor: 4.291

5.  A monoclonal antibody against human T suppressor lymphocytes binds specifically to the surface of cultured oligodendrocytes.

Authors:  J Oger; S Szuchet; J Antel; B G Arnason
Journal:  Nature       Date:  1982-01-07       Impact factor: 49.962

6.  T cell subsets in multiple sclerosis. A longitudinal study of exacerbating-remitting cases.

Authors:  M A Bach; C Martin; P Cesaro; J F Eizenbaum; J D Degos
Journal:  J Neuroimmunol       Date:  1985 Feb-Mar       Impact factor: 3.478

7.  Lymphocyte subpopulations in patients with multiple sclerosis.

Authors:  A Compston
Journal:  J Neurol Neurosurg Psychiatry       Date:  1983-02       Impact factor: 10.154

8.  Fluctuations of CD4+ T-cell subsets in remitting-relapsing multiple sclerosis.

Authors:  L M Rose; A H Ginsberg; T L Rothstein; J A Ledbetter; E A Clark
Journal:  Ann Neurol       Date:  1988-08       Impact factor: 10.422

9.  Peripheral blood T lymphocyte changes in multiple sclerosis: a marker of disease progression rather than of relapse?

Authors:  A J Thompson; J Brazil; C A Whelan; E A Martin; M Hutchinson; C Feighery
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-08       Impact factor: 10.154

10.  Lymphokine regulation of CD45R expression on human T cell clones.

Authors:  S A Brod; C E Rudd; M Purvee; D A Hafler
Journal:  J Exp Med       Date:  1989-12-01       Impact factor: 14.307

View more
  3 in total

1.  Differences in systemic and central nervous system cellular immunity relevant to relapsing-remitting multiple sclerosis.

Authors:  Makoto Matsui; Shin-ichi Araya; Hui-Yun Wang; Kouji Matsushima; Takahiko Saida
Journal:  J Neurol       Date:  2005-03-21       Impact factor: 4.849

Review 2.  Lymphocyte subsets as prognostic markers for cancer patients receiving immunomodulative therapy.

Authors:  M Hernberg
Journal:  Med Oncol       Date:  1999-09       Impact factor: 3.064

3.  Peripheral blood lymphocytes immunophenotyping predicts disease activity in clinically isolated syndrome patients.

Authors:  Helena Posová; Dana Horáková; Václav Čapek; Tomáš Uher; Zdenka Hrušková; Eva Havrdová
Journal:  BMC Neurol       Date:  2017-07-28       Impact factor: 2.474

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.